THERMO FISHER SCIENTIFIC INC.
For the period ended Mar 28, 2026. Filed May 1, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 28, 2026 · Filed May 1, 2026
TMO$694.76+2.6%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets
| March 28, | December 31, | |
|---|---|---|
| (In millions except share and per share amounts) | 2026 | 2025 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $3,254 | $9,852 |
| Short-term investments | 2 | 253 |
| Accounts receivable, less allowances of $149 and $147 | 9,204 | 8,900 |
| Inventories | 5,496 | 5,425 |
| Contract assets, net | 1,684 | 1,666 |
| Other current assets | 2,677 | 2,612 |
| Total current assets | 22,316 | 28,707 |
| Property, plant and equipment, net | 10,658 | 10,565 |
| Acquisition-related intangible assets, net | 19,146 | 15,838 |
| Other assets | 5,973 | 5,871 |
| Goodwill | 55,187 | 49,362 |
| Total assets | $113,281 | $110,343 |
| Liabilities, redeemable noncontrolling interest and equity | ||
| Current liabilities: | ||
| Short-term obligations and current maturities of long-term obligations | $3,090 | $3,533 |
| Accounts payable | 3,344 | 3,622 |
| Accrued payroll and employee benefits | 1,565 | 1,995 |
| Contract liabilities | 2,928 | 2,710 |
| Other accrued expenses | 3,694 | 3,329 |
| Total current liabilities | 14,621 | 15,189 |
| Deferred income taxes | 2,107 | 1,493 |
| Other long-term liabilities | 4,421 | 4,273 |
| Long-term obligations | 40,071 | 35,852 |
| Redeemable noncontrolling interest | 121 | 122 |
| Equity: | ||
| Thermo Fisher Scientific Inc. shareholders’ equity: | ||
| Preferred stock, $100 par value, 50,000 shares authorized; none issued | — | — |
| Common stock, $1 par value, 1,200,000,000 shares authorized; 445,473,074 and 445,160,301 shares issued | 445 | 445 |
| Capital in excess of par value | 18,713 | 18,563 |
| Retained earnings | 60,632 | 59,156 |
| Treasury stock at cost, 73,851,609 and 68,938,831 shares | (25,360) | (22,309) |
| Accumulated other comprehensive income/(loss) | (2,497) | (2,448) |
| Total Thermo Fisher Scientific Inc. shareholders’ equity | 51,934 | 53,407 |
| Noncontrolling interests | 7 | 7 |
| Total equity | 51,940 | 53,415 |
| Total liabilities, redeemable noncontrolling interest and equity | $113,281 | $110,343 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.